Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active

$510,579U19FY2014AINIH

Boston Medical Center, Boston MA

Investigators

Padmini Salgamecontact David Alland

Linked publications, trials & patents

Paper 37461515 Paper 36813297 Paper 36400796 Paper 35738280 Paper 35659006 Paper 35505475 Paper 35273063 Paper 35173157 Paper 35015839 Paper 34847084 Paper 33619056 Paper 33468684 Paper 33387480 Paper 33199862 Paper 33098773 Paper 33038764 Paper 32978384 Paper 32855987 Paper 32785687 Paper 32678272 Paper 32631825 Paper 32417884 Paper 32401195 Paper 32211747 Paper 32091388 Paper 32090859 Paper 32005309 Paper 31689133 Paper 31602294 Paper 31419285 Paper 31205972 Paper 31080069 Paper 30932391 Paper 30840702 Paper 30797860 Paper 30683239 Paper 30619306 Paper 30514497 Paper 30487797 Paper 30476125 Paper 30372480 Paper 30333612 Paper 30325773 Paper 30286038 Paper 30157391 Paper 30012767 Paper 30001743 Paper 29970199 Paper 29921861 Paper 29844114 Paper 29665946 Paper 29522744 Paper 29348181 Paper 29339504 Paper 29298757 Paper 29057058 Paper 29049930 Paper 28821234 Paper 28459619 Paper 28396391 Paper 28370491 Paper 28369607 Paper 28150302 Paper 28061953 Paper 27795387 Paper 27780773 Paper 27763570 Paper 27573104 Paper 27222539 Paper 26642354 Paper 26038289 Paper 25589549

Abstract

The currently available tuberculin skin test (TST) and interferon gamma release assays (IGRA) cannot distinguish between infected persons who i) contain the infection and eliminate the organism (

View original record on NIH RePORTER →